Slide 1: SoftOx Solutions AS Presentation Q1 2022
SoftOx Solutions AS Norwegian medtech and biotech company listed on Euronext Growth Presentation Q1 2022 28 April 2022 Questions: ir@soft-ox.com
Slide 2: Disclaimer
Disclaimer This Presentation has been produced by SoftOx Solutions AS (the “Company” or “SoftOx”), solely for use at the presentation to investors held in connection with Q1 held by the Company. This presentation is strictly confidential and may not be reproduced or redistributed, in whole or in par
Slide 3: Presenters
Presenters Highlights & SoftOx in brief CEO Geir Almås Project updates CMO Dr Glenn Gundersen Financial update CFO Kristine Rød 3 | 1st quarter results 2022 Questions: ir@soft-ox.com
Slide 4: First quarter highlights and SoftOx in brief
01 First quarter highlights and SoftOx in brief 4 | 1st quarter results 2022
Slide 5: First quarter highlights
First quarter highlights RESEARCH & DEVELOPMENT& DEVELOPMENT • SIS-01 is progressing as planned, and the last subject last visit was completed in April • SBE-01 has improved patient enrolment and advanced to the fourth and final dose-level • Premarket Notification (510(k)) application submitted to o
Slide 6: Reinforcing nature's own ability to eradicate unwanted microbes
Reinforcing nature’s own ability to eradicate unwanted microbes HYPOCHLOROUS ORGANIC ACID ACID Documented broad Antimicrobial SOFTOX TECHNOLOGY antimicrobial effect stabilizer Replicating millions of years of evolution A base technology tailored for different indications and uses 6 | 1st quarter res
Slide 7: Helping the world fighting infections
Helping the world fighting infections VIRUS BIOFILM RESISTANCE ANTIMICROBIAL RESISTANCE Respiratory infectious diseases are 1-2% of the population are projected AMR is regarded as one of the among the leading causes of death [1 to experience a chronic wound during biggest threats to global health [3
Slide 8: Business strategy
Business strategy PARTNERS Preclinical Proof Clinical Proof Concept development PARTNERING of Concept of Concept DE-RISKING Investment phase Cash flow SoftOx’s core activities involve research and development before partnering up 8 | 1st quarter results 2022 Questions: ir@soft-ox.com
Slide 9: Business segments
Business segments Wounds Respiratory Disinfection Infection prevention and Infection treatment for Infection prevention treatment for acute and viral infections solutions for hands and chronic wounds surfaces 9 | 1st quarter results 2022 Questions: ir@soft-ox.com
Slide 10: Project updates
02 Project updates 10 | 1st quarter results 2022
Slide 11: Competitive advantage
Competitive advantage 1. Unique chemical stability and quality 2. Strong antimicrobial effects 3. Non-toxic, excellent tolerability 4. Does not induce microbial resistance 5. Technology protected with extensive patent portfolio 6. Technology platform suitable for several needs 11 | 1st quarter resul
Slide 12: Product pipeline
Product pipeline PARTNERS Preclinical Proof Clinical Proof Concept development PARTNERING of Concept of Concept SOFTOX DISINFECTION SOFTOX WOUND IRRIGATION SOLUTION SOFTOX BIOFILM ERADICATOR SOFTOX INHALATION SOLUTION 12 | 1st quarter results 2022 Questions: ir@soft-ox.com
Slide 13: Unmet need in wound care
Unmet need in wound care Wound ACUTE WOUNDS CHRONIC WOUNDS 180 million 40 million 1-2% of population are projected to have a Individuals have skin wounds worldwide each year[4 Chronic wounds worldwide[4 chronic wound in developed countries[5 Today’s wound rinse market is dominated by saline Biofilm
Slide 14: Wound care – Q1 updates
Wound care – Q1 updates Wound PREMARKET NOTIFICATION (510(k)) SoftOx Wound Irrigation Solution (SWIS) Submitted the Premarket Notification (510(k)) application to the US FDA to obtain clearance for SWIS as a medical device class II » Well tolerated in wounds » Skin friendly » Excellent wound healing
Slide 15: Respiratory unmet need: flu-like symptoms
12% of the EU/US population experiences flu-like Respiratory symptoms annually Influenza Waterfall Chart OTC products focused on reducing symptoms, 30% 100% but not: Unmet Need • curing disease, 25% • shortening the duration of disease, Percentage of patients with • altering the course of the diseas
Slide 16: Respiratory – Q1 updates
Respiratory – Q1 updates Respiratory SIS-01 STUDY AIM Explore the safety and tolerability of single and multiple ascending doses of the inhaled nebulised SIS in healthy volunteers SIS-01 ENROLMENT Progressed as planned and the completion of the last subject last visit was announced in April SoftOx I
Slide 17: Disinfection – Q1 updates
Disinfection – Q1 updates Disinfection Major cost 25-55% drivers of HAIs of health care workers Direct relationship between (HCWs) have irritated skin hand hygiene compliance and eczema[6 and HAIs[7 PROOF OF SALES Norway – HINAS tender period began January 2022 Sweden – Tender period is valid from A
Slide 18: Financial update
03 Financial update 18 | 1st quarter results 2022
Slide 19: Financial highlights
Financial highlights Profit and loss statement Accounts for Q1 and FY 2021 SoftOx Solutions Group Operating revenue NOK 1,000 Q1 2022 Q1 2021 Change FY 2021 Low operating income due to Operating revenue 50 412 1 788 low sales Grants 999 1 071 6 113 Total operating revenues 1 049 1 483 -29% 7 901 Ope
Slide 20: Financial highlights
Financial highlights Cash flow statement Q1 2022 Q1 2021 FY 2021 Net change in cash and cash equivalents SoftOx Solutions Group NOK 1,000 -21 141 -20 410 -72 561 Cash flow from operating activities • Strong focus on the product Net result before taxes -24 276 -22 500 -86 291 development and commerci
Slide 21: Summary
04 Summary 21 | 1st quarter results 2022
Slide 22: Multiple opportunities for development of products based on SoftOx technology
Multiple opportunities for development of products based on SoftOx technology Opportunity X Opportunity X Opportunity X Opportunity X Animal infection Defense Opportunity X treatment multiproduct Opportunity X Biofilm Eradicator (SBE) Defense Opportunity X countermeasure Opportunity X Wound Irrigati
Slide 23: Expected news flow 2022
Expected news flow 2022 SoftOx Wound Irrigation Solution (SWIS) • Talks with major distributors • GMP production line • Establishing a QMS for medical devices • Achieve a 510K clearance for the US market SoftOx Biofilm Eradicator (SBE) • Complete patient enrolment of the SBE-01a single dose study •
Slide 24: Key takeaways
Key takeaways Solid progress on Highly Endogeneous the projects targeting Strong platform skilled team ingredients large global 12 PhDs & 3 Well known & with great potential for many products/segments markets professors/researchers well tolerated by human body 58 granted Commercial Huge unmet Collab
Slide 25: Contact Information: ir@soft-ox.com
New ways of eradicating infections and fighting antimicrobial resistance Contact Information: ir@soft-ox.com Geir Hermod Almås Kristine Mundal Rød Chief Executive Officer Chief Financial Officer